Core Viewpoint - The company, Weilan Bio (603739.SH), emphasizes its commitment to technological innovation and global expansion, aiming to establish itself as a leading industrial biotechnology platform through increased R&D investment and international market development [1] Financial Performance - In the first half of 2025, the company reported a revenue of 652.19 million yuan, representing a year-on-year growth of 7.05% [1] - The net profit attributable to shareholders was 26.72 million yuan, showing a decline of 8.98% compared to the previous year [1] R&D Investment - The company invested 63.88 million yuan in R&D during the first half of 2025, accounting for 9.80% of its revenue, which reflects a year-on-year increase of 16.04% [1] Strategic Focus - The company is optimizing its service solutions and operational efficiency to enhance its core competitiveness while deepening its "Belt and Road" industrial layout to promote international market expansion [1]